French penny stock will no longer knock on FDA door for approval in a certain type of blood cancer
Things are not looking up for the French biotech Erytech Pharma.
The company is knocking off its plan to get FDA approval for its drug Graspa in hypersensitive acute lymphoblastic leukemia (ALL), following feedback from the regulators, it said in a press release Wednesday afternoon. ALL is the common type of childhood cancer diagnosed in approximately 5,000 new cases each year in the United States.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.